Active-ingredient Dossier
Cladribine
Active-ingredient Dossier for Cladribine (purine nucleoside antimetabolite). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: LEUSTATIN
- Brand: MAVENCLAD
- Brand: LITAK
- Brand: CLADRITAB
- Therapeutic area: Neurology
- Therapeutic area: Oncology
What is
Cladribine Cladribine is a purine nucleoside antimetabolite.
Australian brands containing
Cladribine — LEUSTATIN — MAVENCLAD — LITAK — CLADRITAB
Therapeutic areas
Cladribine is registered in two therapeutic areas: neurology, with two brands, and oncology, with two brands.
Sponsor landscape
Three sponsors market cladribine-containing products in Australia: Merck Healthcare, Atnahs Pharma, and Viatris.
PBS and regulatory activity
Two brands containing cladribine have PBS-listed items, with the latest PBS schedule date being 1 May 2026. In the 2023–24 financial year, government expenditure on cladribine products was $76,307,661 across 4,725 scripts. Three brands have PBAC outcomes on record, with the latest PBAC review occurring on 1 November 2023. One brand has an AusPAR on record, dated 5 December 2017.